Rifasutenizol-Based Triple Therapy Versus Bismuth Plus Clarithromycin Triple Therapy for First-Line Helicobacter pylori Eradication: Analysis of the EVEREST-HP Phase 3 Trial in China

Highlights

• Rifasutenizol (TNP-2198), a novel antimicrobial with dual mechanism, shows high efficacy against H. pylori, including resistant strains.
• In the EVEREST-HP phase 3 trial, rifasutenizol-based triple therapy (RTT) achieved a 92.0% eradication rate, non-inferior to bismuth plus clarithromycin-based triple therapy (BCTT) at 87.9%.
• RTT demonstrated a better safety and tolerability profile, with significantly fewer treatment-emergent adverse events, notably reduced taste perversion compared to BCTT.
• All cultured H. pylori isolates were susceptible to rifasutenizol, highlighting its potential role in overcoming clarithromycin resistance.

Background